Concord Biotech Limited

BSE: 543960 NSE: CONCORDBIO
Concord Biotech Limited - chemicals in Ahmedabad, Gujarat, India. FY 2026 financials & compliance.
CIN L24230GJ1984PLC007440 Incorporated 23 November 1984 ROC Ahmedabad HQ Ahmedabad, Gujarat, India
Active Listed - NSE: CONCORDBIO · BSE: 543960 Public Limited Company chemicals Nifty 500
Data last updated
Market Cap
₹12,809 Cr
CONCORDBIO · NSE
Share Price
₹601.10
-1.81% today
Revenue
₹1,055 Cr
FY 2025-26 · -12.1% YoY
EBITDA
₹365 Cr
Margin 34.6%
Net Profit
₹239 Cr
FY 2025-26 · -30.7% YoY
P/E (TTM)
46.5x
P/B 6.4x
ROE
13.5%
ROCE 18.0%
Authorised capital
₹11 Cr
Registered with MCA

About Concord Biotech Limited

Data last updated:

Concord Biotech Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the chemical products segment of the chemicals sector. It was incorporated on 23 November 1984 and has been in existence for over 42 years.

Concord Biotech is part of the Nifty 500 and BSE 500 indices. Its director Sudhir Vaid and family are #441 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ1984PLC007440. Its GSTIN is 24AAACC8514G1ZZ (Gujarat). The company holds 4 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 543960 and NSE: CONCORDBIO.

The company has an authorised share capital of ₹11 Cr and a paid-up capital of ₹10.46 Cr. It was formerly known as Servomed Pharmaceuticals Private Limited and Servomed Pharmaceuticals Limited. It is led by directors including Ankur Vaid (Managing Director) and Sudhir Jairam Vaid (Managing Director).

Its last annual general meeting (AGM) was held on 31 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 1482 – 86 Trasad Road Dholka, Ahmedabad, Gujarat, India – 387810.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,054.89 Cr, a decline of 12.1% compared to the previous year. For the same year it recorded a net profit of ₹238.57 Cr (net margin 22.6%) and EBITDA of ₹364.67 Cr (EBITDA margin 34.6%). The net worth stands at ₹2,017.06 Cr (up 11.3% YoY). Total assets are valued at ₹2,021.17 Cr (up 11.1% YoY).

The company has about 1,516 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Concord Biotech. As per MCA filings, the company has open charges of ₹45 Cr and satisfied charges of ₹154.77 Cr on record. Court records list 22 cases involving the company, including 10 filed by the company and 12 filed against it; 6 cases are pending. The company has 24 deals on record (15 secondary share transfers, 6 market trades, 2 funding rounds), with disclosed funding of ₹77.51 Cr; the latest was in August 2026. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 11 overdue payments to 3 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website concordbiotech.com.

Company details

CIN L24230GJ1984PLC007440
Registration Number 007440
Incorporation Date 23 November 1984
ROC Ahmedabad
Listing Status Listed - Listed on NSE (CONCORDBIO); Listed on BSE (543960)
Company Status Active
Date of Last AGM 31 July 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Concord Biotech has undergone 2 name changes throughout its history. The company was previously known as Servomed Pharmaceuticals Private Limited, and Servomed Pharmaceuticals Limited. The current legal name is Concord Biotech Limited.

Company NameStatus
Concord Biotech LimitedCurrent
Servomed Pharmaceuticals Private LimitedPrevious
Servomed Pharmaceuticals LimitedPrevious

CIN history

Concord Biotech has one previous CIN (Corporate Identification Number): U24230GJ1984PLC007440. The current CIN is L24230GJ1984PLC007440, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24230GJ1984PLC007440Current
U24230GJ1984PLC007440Previous
Key People
Ankur Vaid Managing Director Sudhir Jairam Vaid Managing Director Arvind Motilal Agarwal Director

Recognitions & Rankings of Concord Biotech

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#259
Valuation
₹21,950 Cr
2023 #308
India's Richest People 2026 edition · 1 director · Source: Hurun India
Stock market indices
Nifty 500 BSE 500

Contact details

Concord Biotech Limited's registered office is in Ahmedabad, Gujarat. Its website is concordbiotech.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    concordbiotech.com
  • Social Media
  • Registered Address
    1482 – 86 Trasad Road Dholka, Ahmedabad, Gujarat, India – 387810
  • Industry
    Chemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals

To see the full contact details of Concord Biotech Limited, buy the company report.

Comprehensive company report
Concord Biotech Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Concord Biotech operates one associated brand: Concord Biotech. Each brand links to its own profile.

BrandDescriptionWebsite
Concord Biotech
APIs and enzymes are manufactured through fermentation by the CDMO.concordbiotech.com

Business activity

The main business activity of Concord Biotech is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Concord Biotech Limited, buy the company report.

Financials of Concord Biotech Limited

FY 2025-26 filings available

Concord Biotech Limited reported revenue of ₹1,054.89 Cr (down 12.1% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,055 Cr
-12.1% YoY
EBITDA
₹365 Cr
-27.9% YoY
Profit After Tax
₹239 Cr
-30.7% YoY
Net Worth
₹2,017 Cr
+11.3% YoY
Total Assets
₹2,021 Cr
+11.1% YoY
Total Debt
₹2.32 Cr
-21.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,0551,2001,017853713616512
Revenue growth-12.1%+18.0%+19.2%+19.7%+15.7%+20.3%-
EBITDA365506432344270327205
EBITDA margin+34.6%+42.1%+42.5%+40.3%+37.9%+53.1%+39.9%
Profit before tax345495413322238313214
Net profit239344298237171230152
Net profit margin+22.6%+28.7%+29.3%+27.8%+24.0%+37.4%+29.6%
EPS (₹)24.9435.5229.4522.95183.93247.44177.82
Balance sheet
Total assets2,0211,8191,5381,3241,1681,089824
Net worth2,0171,8131,5271,2901,103999770
Total debt2.322.979.7431.5562.5086.3552.06
Cash & bank13.581.1847.0243.4588.9360.822.59
Net working capital680637518424435391239
Cash flow
Cash from operations267245265246207167155
Cash from investing(143)(160)(155)(158)(112)(195)(114)
Cash from financing(113)(98.77)(99.21)(85.22)(100)31.37(42.52)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue309257326278247204430244
Revenue growth (YoY)+25.1%+26.2%-24.2%+13.7%-20.4%-5.5%--
Other income10.1714.1015.359.9815.6415.179.3816.56
EBITDA10482.3811895.0188.4961.4018997.95
EBITDA margin+33.6%+32.0%+36.3%+34.2%+35.8%+30.1%+43.9%+40.1%
Depreciation18.3818.1019.5418.7518.3917.7814.6213.26
Interest0.030.040.080.080.060.060.100.10
Profit before tax95.4878.3411486.1685.6858.73184101
Tax25.9120.6525.6122.5222.6314.6843.1625.23
Net profit69.5757.6988.4763.6463.0544.0514075.92
EPS (₹)6.655.528.466.086.034.2113.427.26
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,0551,2001,017853713617512
Revenue growth-12.1%+18.0%+19.2%+19.7%+15.6%+20.4%-
EBITDA374507432344274328205
EBITDA margin+35.4%+42.2%+42.5%+40.3%+38.4%+53.2%+39.9%
Profit before tax351496409320241313213
Net profit241345294235175230151
Net profit margin+22.8%+28.8%+28.9%+27.6%+24.5%+37.3%+29.6%
EPS (₹)25.1735.6529.1322.76187.76247.44177.66
Balance sheet
Total assets2,0241,8181,5371,3261,1721,091824
Net worth2,0201,8131,5251,2921,1071,000770
Total debt0.632.979.7431.5562.5089.2852.06
Cash & bank9.281.1847.0243.4588.9360.822.59
Net working capital676637518425438392239
Cash flow
Cash from operations264245265246207167155
Cash from investing(142)(160)(155)(158)(112)(195)(114)
Cash from financing(115)(98.77)(99.21)(85.22)(100)31.12(42.52)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue312261326278247204430244
Revenue growth (YoY)+26.4%+27.7%-24.2%+13.9%-20.4%-5.5%--
Other income10.4513.1015.5410.0813.4313.689.3814.73
Total expenses202173204179157143239146
EBITDA11087.1812298.9490.5461.4019097.95
EBITDA margin+35.2%+33.5%+37.6%+35.6%+36.6%+30.1%+44.3%+40.1%
Depreciation18.3418.0519.4918.6718.3917.7814.6213.26
Interest0.010.020.060.060.060.060.100.10
Profit before tax10282.2111890.2985.5257.2418599.32
Tax26.2121.0228.3622.5222.6314.6843.1625.23

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 09 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue309257326278247204430244
Revenue growth (YoY)+25.1%+26.2%-24.2%+13.7%-20.4%-5.5%--
Other income10.1714.1015.359.9815.6415.179.3816.56
EBITDA10482.3811895.0188.4961.4018997.95
EBITDA margin+33.6%+32.0%+36.3%+34.2%+35.8%+30.1%+43.9%+40.1%
Depreciation18.3818.1019.5418.7518.3917.7814.6213.26
Interest0.030.040.080.080.060.060.100.10
Profit before tax95.4878.3411486.1685.6858.73184101
Tax25.9120.6525.6122.5222.6314.6843.1625.23
Net profit69.5757.6988.4763.6463.0544.0514075.92
EPS (₹)6.655.528.466.086.034.2113.427.26
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,0551,2001,017853713616512
Revenue growth-12.1%+18.0%+19.2%+19.7%+15.7%+20.3%-
Other income55.2644.4537.1537.2723.4214.1031.52
Total expenses690695585509443289308
Employee cost17713912311095.6964.2562.24
EBITDA365506432344270327205
EBITDA margin+34.6%+42.1%+42.5%+40.3%+37.9%+53.1%+39.9%
Depreciation74.4654.3753.5954.0350.0527.5221.25
Interest0.821.043.185.186.130.901.17
Profit before tax345495413322238313214
Tax85.4212310481.9362.5977.8344.53
Net profit239344298237171230152
Net profit margin+22.6%+28.7%+29.3%+27.8%+24.0%+37.4%+29.6%
EPS (₹)24.9435.5229.4522.95183.93247.44177.82
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.4610.4610.4610.469.519.519.51
Reserves & surplus2,0071,8021,5161,2801,094990761
Shareholders' funds (net worth)2,0171,8131,5271,2901,103999770
Minority interest(1.92)0.000.000.000.000.000.00
Secured loans0.000.386.2331.2460.5961.3535.53
Unsecured loans2.322.593.510.311.9125.0016.53
Total debt2.322.979.7431.5562.5086.3552.06
Total liabilities2,0211,8191,5381,3241,1681,089824
Assets
Gross block1,1611,095826792720643310
Net block789795575593573546240
Capital work in progress79.3250.6621117374.1617.95141
Investments49133524613773.73141199
Inventories326240208212195154111
Sundry debtors460522350274232178184
Cash & bank balances13.581.1847.0243.4588.9360.822.59
Loans & advances47.9256.2047.9461.2542.9774.2243.37
Total current assets848819653591559466341
Total current liabilities16818213416712475.64102
Net working capital680637518424435391239
Total assets2,0211,8191,5381,3241,1681,089824
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.9015.143.500.675.142.413.76
Net cash from operating activities267245265246207167155
Net cash from investing activities(143)(160)(155)(158)(112)(195)(114)
Net cash from financing activities(113)(98.77)(99.21)(85.22)(100)31.37(42.52)
Net change in cash11.28(14.24)11.642.83(4.48)2.74(1.35)
Closing cash13.581.1847.0243.4588.9360.822.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-12.1%+18.0%+19.2%+19.7%+15.7%+20.3%-
EBITDA growth-27.9%+17.0%+25.6%+27.3%-17.5%+60.1%-
PBT growth-30.3%+19.9%+28.1%+35.6%-24.2%+46.6%+9997.0%
Net income growth-30.7%+15.6%+25.4%+38.8%-25.7%+51.9%-
Revenue CAGR (3Y)+7.3%+19.0%+18.2%+18.5%---
EBITDA CAGR (3Y)+2.0%+23.2%+9.7%+18.9%---
Profitability & leverage
Net income margin+24.6%+31.0%+30.3%+28.1%+24.5%+38.2%+33.0%
Return on capital employed+18.0%+29.5%+29.1%+26.3%+21.6%+32.8%+23.2%
Return on net worth+13.5%+22.3%+21.9%+20.1%+16.6%+26.6%+19.7%
Debt / equity0.000.000.010.040.070.080.07
Long-term debt / equity0.000.000.000.020.040.050.05
Interest cover0.280.230.841.792.780.300.64
Efficiency & per share
Fixed asset turnover0.931.251.261.131.051.291.65
Inventory turnover3.735.364.844.194.094.654.61
Debtors turnover2.152.753.263.373.483.412.79
EPS (₹)24.9435.5229.4522.95183.93247.44177.82
Dividend per share (₹)7.5510.708.756.835.120.0039.25
Book value per share (₹)192.81173.27145.93123.311,159.991,050.80809.87
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue312261326278247204430244
Revenue growth (YoY)+26.4%+27.7%-24.2%+13.9%-20.4%-5.5%--
Other income10.4513.1015.5410.0813.4313.689.3814.73
Total expenses202173204179157143239146
EBITDA11087.1812298.9490.5461.4019097.95
EBITDA margin+35.2%+33.5%+37.6%+35.6%+36.6%+30.1%+44.3%+40.1%
Depreciation18.3418.0519.4918.6718.3917.7814.6213.26
Interest0.010.020.060.060.060.060.100.10
Profit before tax10282.2111890.2985.5257.2418599.32
Tax26.2121.0228.3622.5222.6314.6843.1625.23
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,0551,2001,017853713617512
Revenue growth-12.1%+18.0%+19.2%+19.7%+15.6%+20.4%-
Other income52.7344.4533.7835.3123.4213.8131.37
Total expenses681693585509439289308
Employee cost17013912311095.6969.4762.24
EBITDA374507432344274328205
EBITDA margin+35.4%+42.2%+42.5%+40.3%+38.4%+53.2%+39.9%
Depreciation74.3354.3753.5954.0350.0527.5221.25
Interest0.771.043.185.186.131.051.17
Profit before tax351496409320241313213
Tax88.1612310481.9362.5977.8344.53
Net profit241345294235175230151
Net profit margin+22.8%+28.8%+28.9%+27.6%+24.5%+37.3%+29.6%
EPS (₹)25.1735.6529.1322.76187.76247.44177.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.4610.4610.4610.469.519.519.51
Reserves & surplus2,0091,8021,5151,2821,098990761
Shareholders' funds (net worth)2,0201,8131,5251,2921,1071,000770
Secured loans0.000.386.2331.2460.5986.3535.53
Unsecured loans0.632.593.510.311.912.9316.53
Total debt0.632.979.7431.5562.5089.2852.06
Total liabilities2,0241,8181,5371,3261,1721,091824
Assets
Gross block1,1591,095826792720644310
Net block786795575593573546240
Capital work in progress79.3250.6621117374.1617.95141
Investments48833524413874.39142199
Inventories326240208212195154111
Sundry debtors461522350274232178184
Cash & bank balances9.281.1847.0243.4588.9360.822.59
Loans & advances47.5856.2047.9461.2542.9774.2243.37
Total current assets843819653591559466341
Total current liabilities16718213416512174.34102
Net working capital676637518425438392239
Total assets2,0241,8181,5371,3261,1721,091824
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.9015.143.500.675.142.413.76
Net cash from operating activities264245265246207167155
Net cash from investing activities(142)(160)(155)(158)(112)(195)(114)
Net cash from financing activities(115)(98.77)(99.21)(85.22)(100)31.12(42.52)
Net change in cash6.98(14.24)11.642.83(4.48)2.74(1.35)
Closing cash9.281.1847.0243.4588.9360.822.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-12.1%+18.0%+19.2%+19.7%+15.6%+20.4%-
EBITDA growth-26.3%+17.3%+25.6%+25.6%-16.5%+60.3%-
PBT growth-29.1%+21.2%+27.8%+32.7%-23.0%+46.7%+20.0%
Net income growth-30.3%+17.4%+25.0%+34.8%-24.1%+51.9%-
Revenue CAGR (3Y)+7.3%+19.0%+18.1%+18.5%+17.8%+22.0%+22.9%
EBITDA CAGR (3Y)+2.8%+22.8%+9.6%+18.9%+14.9%+31.3%+14.8%
Profitability & leverage
Net income margin+25.0%+31.1%+30.0%+27.9%+25.1%+38.2%+33.0%
Return on capital employed+18.3%+29.6%+28.8%+26.1%+21.9%+32.8%+25.2%
Return on net worth+13.7%+22.4%+21.6%+19.9%+17.0%+26.6%+20.9%
Debt / equity0.000.000.010.040.070.080.04
Long-term debt / equity0.000.000.000.020.040.050.03
Interest cover0.260.230.841.792.740.350.64
Efficiency & per share
Fixed asset turnover0.941.251.261.131.051.291.73
Inventory turnover3.735.364.844.194.094.665.05
Debtors turnover2.152.753.263.373.483.423.00
EPS (₹)25.1735.6529.1322.76187.76247.44177.66
Dividend per share (₹)7.5510.708.756.835.120.0039.25
Book value per share (₹)193.06173.27145.80123.501,164.131,051.11809.71

To see the full year-wise statements and ratios of Concord Biotech Limited, buy the company report.

Board of directors of Concord Biotech Limited

Concord Biotech has 10 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Arvind Motilal Agarwal
Also directs: KLJ Plasticizers Limited.
Director24 May 20224 Years 5 MonthsCurrent
Ravi Kapoor
Also directs: Amity Consultants LLP, Yan Advisory Services LLP, Orient Cement Limited and 5 more
Director15 Dec 200322 Years 10 MonthsCurrent
Rajiv Ambrish Agarwal
Also directs: Tiger Consultancy LLP, Aptech Limited, Hungama Digital Media Entertainment Private Limited and 3 more
Director30 Jun 200818 Years 4 MonthsCurrent
Ankur Vaid
Also directs: Sudman Consultants LLP, Celliimune Biotech Private Limited
Managing Director01 Sep 201115 Years 2 MonthsCurrent
Sudhir Jairam Vaid
Also directs: Sudman Consultants LLP
Managing Director14 Feb 201115 Years 8 MonthsCurrent
Bharti Khanna
Also directs: Amarant Lifesciences Private Limited
Director31 Jan 20179 Years 9 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Auditor

Concord Biotech Limited is audited by B S R & CO.LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
B S R & CO.LLPFY 2025101248W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 44.10%, foreign institutional investors hold 7.50%, domestic institutional investors hold 9.40% and retail and other public shareholders hold 39.00%.

Promoters: 44.10%DII (Domestic Institutional): 9.40%FII (Foreign Institutional): 7.50%Retail & Others: 39.00%
Sep 2026
QUARTER
44.10% Promoters
9.40% DII (Domestic Institutional)
7.50% FII (Foreign Institutional)
39.00% Retail & Others
Promoter holding - history
Now 44.10% · Sep 2026High 44.10% · Dec 2025Low 44.10% · Dec 2025
43%43.8%44.5%45.3%46%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 44.10%Mar 2026: 44.10%Jun 2026: 44.10%Sep 2026: 44.10%44.10%44.10%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters44.10%44.10%44.10%44.10%
Public55.90%55.90%55.90%55.90%

Charges & borrowings

Open charges
₹45 Cr
Satisfied charges
₹154.77 Cr
Breakdown by lending institutions
Axis Bank Limited₹45.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
27 Jan 200390099613Axis Bank Limited₹45 CrOpen
17 Oct 2019100298054State Bank of India₹110 CrSatisfied
11 Aug 201510588016Citi Bank N.A.₹30.82 CrSatisfied
09 Dec 201410542701Citi Bank N.A.₹10 CrSatisfied
23 Jan 201210336441Citibank N. A.₹3.7 CrSatisfied

To see the full charge records of Concord Biotech Limited, buy the company report.

Total charge records: 6 View all charges

Deals & funding

Concord Biotech Limited has 24 deals on record (15 secondary share transfers, 6 market trades, 2 funding rounds), with disclosed funding of ₹77.51 Cr; the latest was in August 2026.

Total deals
24
Secondary share transfers
15
Market trades
6
Funding rounds
2
IPO
1
Disclosed funding
₹77.51 Cr

Deals on record (5 of 24)

WhenDealAmountParties
Feb 2026Market trade₹75.18 CrBuyer: NK Securities Research Private Limited
Seller: NK Securities Research Private Limited
Aug 2023Market trade₹254.98 CrBuyer: NK Securities Research Private Limited , Norges Bank On Account Of The Government Pension Fund Global, Graviton Research Capital LLP
Seller: NK Securities Research Private Limited , Graviton Research Capital LLP
Jan 2021Secondary share transferUndisclosedBuyer: Calculas Financial Consultants Privnate Limited
Seller: Chanakya Corporate Services Private Limited
Mar 2014Secondary share transferUndisclosedBuyer: Chanakya Corporate Services Private Limited , an individual
Seller: Abhigam Shares and Securities Private Limited , an individual
Mar 2009Secondary share transferUndisclosedBuyer: Sudman Consultants LLP
Seller: Satyendra Jha & Sudman Consultants Pvt. Ltd.

To see the full deal history of Concord Biotech Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Concord Biotech Limited was last rated by Icra on 07 Apr 2022.

Rating agencyRated onRating
Icra07 Apr 2022

To see the full credit ratings and regulatory alerts of Concord Biotech Limited, buy the company report.

MSME payment delays

Concord Biotech Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 11 overdue payments to 3 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (3 of 3)

SupplierAmount dueDue sinceReported on
an individual supplier
Sequel Logistics Private Limited
an individual supplier

To see the full MSME payment records of Concord Biotech Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Concord Biotech Limited has a workforce of 1,516 employees on its EPFO records as of Apr 14, 2025, across 1 active EPFO establishment.

Employee count
1,516
Active EPFO establishments
1
Employee growth
13.73%

GST

Concord Biotech has 4 GST registrations: 4 active.

Total GSTINs
4
Active
4
GSTINStateStatusRegistered on
24AAACC8514G1ZZGujaratActive01 Jul 2017
33AAACC8514G1Z0Tamil NaduActive11 Jan 2021
07AAACC8514G1ZVDelhiActive28 Jan 2021
19AAACC8514G1ZQWest BengalActive25 Mar 2021

To see the full GST registrations and return filing status of Concord Biotech Limited, buy the company report.

Recent activity

Concord Biotech Limited has 44 board changes on record since 2003: 27 appointments and 17 cessations. The latest: Ekta Gupta was appointed as Director on 01 Jun 2026.

AGM
Concord Biotech Limited last Annual general meeting of members was held on 31 Jul 2026 as per latest MCA records.
Appointed
Ekta Gupta was appointed as Director.
Filing
Concord Biotech Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Ceased
Ravirajbhai Ghanshyambhai Karia ceased to be CEO.
Charges
A charge registered on 17 Oct 2019 via Charge ID 100298054 with State Bank Of India was fully satisfied on 29 May 2025.
Ceased
Prakash Lalchand Sajnani ceased to be Company Secretary.
Ceased
Utpal Hemendra Sheth ceased to be Director.
Ceased
Anil Katyal ceased to be Director.
Ceased
Amit Varma ceased to be Director.
Charges
A charge with Axis Bank Limited of Rs. 45.00 Cr registered on 27 Jan 2003 with Charge ID 90099613 was modified on 31 Jul 2023.
Appointed
Chakravarthy Sriraman Mandayam was appointed as Director.
Appointed
Jayaram Easwaran was appointed as Director.

49 earlier events are in the company report.

News

CONCORDBIO: Q2 REVENUE 3.12B RUPEES VS 2.47B (YOY)
27 Oct 2026 · Exchange Update
CONCORDBIO: Q2 SL NET PROFIT 757M RUPEES VS 629M (YOY)
27 Oct 2026 · Exchange Update
CONCORDBIO: Q2 EBITDA 1.1B RUPEES VS 905.4M (YOY); Q2 EBITDA MARGIN 35.16% VS 36.65% (YOY)
27 Oct 2026 · Exchange Update

Frequently asked questions

Concord Biotech is an active public limited company based in Ahmedabad, Gujarat, India. The company works in chemical products, within the chemicals industry. It was incorporated on 23 November 1984 (42+ years old) and is registered under CIN L24230GJ1984PLC007440. Listed on BSE: 543960 and NSE: CONCORDBIO.

Concord Biotech reported revenue of ₹1,054.89 Cr for FY 2025-26 (down 12.1% YoY) based on consolidated financials.

Concord Biotech has 10 current directors:

The latest financial statements of Concord Biotech on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 31 July 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Concord Biotech is 24AAACC8514G1ZZ, registered in Gujarat. The company has 4 GST registrations in all, of which 4 are active. Other active GSTINs include 33AAACC8514G1Z0 (Tamil Nadu), 07AAACC8514G1ZV (Delhi), 19AAACC8514G1ZQ (West Bengal).

The CIN (Corporate Identification Number) of Concord Biotech is L24230GJ1984PLC007440. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Concord Biotech is a listed company as per MCA records. Its shares are listed on both BSE (code: 543960) and NSE (symbol: CONCORDBIO).

Concord Biotech has 22 court cases on record: 10 filed by the company and 12 filed against it. 6 are pending. Most are in the district courts.

Concord Biotech was incorporated on 23 November 1984, making it 42+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Concord Biotech has 24 deals on record (15 secondary share transfers, 6 market trades, 2 funding rounds), with disclosed funding of ₹77.51 Cr; the latest was in August 2026.

Ekta Gupta was appointed as Director on 01 Jun 2026. Ravirajbhai Ghanshyambhai Karia ceased to be CEO on 18 Dec 2025. Prakash Lalchand Sajnani ceased to be Company Secretary on 29 May 2025. Concord Biotech has 44 board changes on record in total.